binx health

brand
5.0
321
Network
Score (What’s this?)

Perlu Network score measures the extent of a member’s network on Perlu based on their connections, Packs, and Collab activity.

0
Perlu
Pulse (What’s this?)

Perlu Pulse score measures how active a member is on Perlu, on a scale of 0 to 100.

The biggest decisions are the easiest to avoid. That’s why binx is working to make STI testing routine, fast, easy and as private as you’d like it to be – taking a big, intimidating decision and making it feel small. An activity as convenient and routine as everything else people do to stay healthy. With binx, you can get tested for sexually transmitted infections on your own time, in your own space.

Our mission is to improve sexual health and wellness through new STI testing delivery methods that prioritize clinical integrity and consumer convenience. We provide a first of its kind, comprehensive digital program that includes evidence-based at-home testing, counseling, treatment, and follow up in order to increase STI screenings rates and reduce infections.

Location Boston, MA
Country United States of America
Member Since JULY 17, 2019
Share
Social Audience 979
Blog Monthly Visits 3K
mybinxhealth.com Last Month
  • Moz DA 38
  • Monthly Visits 3K
binxhealth 899 Last Month Last 3 Months
  • Posts 0 0
  • Engagement Rate 0.0% 0.0%
  • Sponsored Posts 0 0
  • Sponsored Engagement Rate 0.0% 0.0%
  • Avg Likes 0 0
  • Avg Comments 0 0
Categories
  • Business and Finance
  • Industries
  • Education
  • College Education
  • Family and Relationships
  • Healthy Living
  • Men's Health
  • Wellness
  • Women's Health
  • Health Podcasts
  • Medical Health
  • Diseases and Conditions
  • Pets
  • Computing
Highlights
binx health Announces Publication of Pivotal Study in JAMA Network Open

The study shows that the binx io provides accurate results in about 30 minutes, enabling single visit test and treatment for chlamydia (CT) and gonorrhea (NG), two of the most tested-for sexually transmitted infections (STIs) globally. The standard of care today for CT/NG testing often requires 2-10 days of delay between sample collection and answer, resulting up to 40% of positive patients not returning for treatment[1]. With CT/NG infections already at record highs—and the broad cessation of routine STI testing related to impacts of COVID-19[2]—the need for the binx io rapid, molecular point-of-care platform is especially acute. Barbara Van Der Pol, MPH, PhD, President of the American Sexually Transmitted Diseases Association and Principal Investigator of the clinical study at the University of Alabama at Birmingham, described the binx io CT/NG assay as “a highly accurate test that allows rapid results to be available during the patient visit. The FDA cleared, binx io system is a highly flexible and easy-to-use, molecular point-of-care platform leveraging patented, multiplex technology to enable central lab equivalent clinical performance in decentralized, near patient locations such as retail pharmacy, urgent care, and the large and evolving category of consumer “super stores,” that are increasingly serving customer health needs.

binx health Announces Second FDA 510(k) Clearance of its Molecular Point-of-Care Infectious Disease Platform

Latest FDA clearance establishes binx as the fastest dual-gender rapid test-and-treat platform for chlamydia and gonorrhea COVID-19 pandemic has created growing backlog of millions in need of routine STI testing binx health, a leader in infectious disease testing solutions, announced that it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) in one of the largest markets for infectious disease testing. Today, the Company announces FDA 510(k) clearance to market its sensitive and specific, molecular point-of-care testing platform, the binx io, for the detection of chlamydia (CT) The binx io platform is a rapid, qualitative, fully automated molecular test, designed to be easy to use, and intended for use at the point of care or clinical laboratory settings. The FDA cleared, binx io system is a highly flexible and easy-to-use, molecular point-of-care platform leveraging patented, multiplex technology to enable central lab equivalent clinical performance in decentralized, near patient locations such as OB-GYN and primary care, retail pharmacy, urgent care, and the large and evolving category of consumer “super stores,” that are increasingly serving customer health needs.

Fortune Magazine featured binx health’s io as a healthcare “breakthrough,” as it expands access to high quality chlamydia and gonorrhea testing at point of care sites across the US

binx health was featured in Fortune Magazine highlighting the io platform as not only the first and fastest FDA-cleared molecular point-of-care diagnostic for the detection of chlamydia and gonorrhea, but also for its potential to be a “breakthrough” in efforts to prevent and control STIs. The FDA cleared, binx io system is a highly flexible and easy-to-use, molecular point-of-care platform leveraging patented, multiplex technology to enable central lab equivalent clinical performance in decentralized, near patient locations such as OB-GYN and primary care, retail pharmacy, urgent care, and the large and evolving category of consumer “super stores,” that are increasingly serving customer health needs. In addition to the binx io onsite care platform above, binx has also developed a suite of medical guideline driven, at-home testing solutions to reach the many who are unwilling or unable to visit a physical location. We believe the future of near-patient healthcare lies at the nexus of testing convenience, rigorous science, and consumer relationships with a rapidly expanding retail health landscape.

Revolutionizing STI Diagnostics

In fact, in a recent multi-center study of the binx point-of-care platform, only half of patients presenting with symptoms actually had an infection and, without the benefit of a rapid test-and-treat diagnostic system, may likely have received unnecessary and inappropriate empiric treatment. : it is the world’s first, FDA-cleared, molecular point-of-care test for the detection of chlamydia (CT) and gonorrhea (NG) in vaginal swabs that generates results, with accuracy equivalent to central lab testing, in about 30 minutes. The io is designed to enable test-to-treatment in a single visit, allowing treatment of a greater number of positive patients more accurately while preventing over-treatment in symptomatic but CT/NG negative patients. The binx ecosystem consists of rapid point-of-care testing, at-home screening, and an integrated set of clinician tools that equip you to improve the sexual health of your patients and curb the rising STI rates.